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OSU-NAG eye plaques use fewer sources than COMS-plaques of comparable size, 
and do not employ a Silastic seed carrier insert. Monte Carlo modeling was used to 
calculate 3D dose distributions for a 16 mm OSU-NAG eye plaque and a 16 mm 
COMS eye plaque loaded with either Iodine-125 or Cesium-131 brachytherapy 
sources. The OSU-NAG eye plaque was loaded with eight sources forming two 
squares, whereas the COMS eye plaque was loaded with thirteen sources approxi-
mating three isocentric circles. A spherical eyeball 24.6 mm in diameter and an 
ellipsoid-like tumor 6 mm in height and 12 mm in the major and minor axes were 
used to evaluate the doses delivered. To establish a fair comparison, a water seed car-
rier was used instead of the Silastic seed carrier designed for the traditional COMS 
eye plaque. Calculations were performed on the dose distributions along the eye 
plaque axis and the DVHs of the tumor, as well as the 3D distribution. Our results 
indicated that, to achieve a prescription dose of 85 Gy at 6 mm from the inner sclera 
edge for a six-day treatment, the OSU-NAG eye plaque will need 6.16 U/source and  
6.82 U/source for 125I and 131Cs, respectively. The COMS eye plaque will require 
4.02 U/source and 4.43 U/source for the same source types. The dose profiles of 
the two types of eye plaques on their central axes are within 9% difference for all 
applicable distances. The OSU-NAG plaque delivers about 10% and 12% more dose 
than the COMS for 125I and 131Cs sources, respectively, at the inner sclera edge, 
but 6% and 3% less dose at the opposite retina. The DVHs of the tumor for two 
types of plaques were within 6% difference. In conclusion, the dosimetric quality 
of the OSU-NAG eye plaque used in eye plaque brachytherapy is comparable to 
the COMS eye plaque. 
PACS number: 87.56B, 87.55k, 87.55kh
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I. INtrOdUCtION
Eye plaque brachytherapy is a well-recognized treatment technique for the management of ocular 
melanomas. According to clinical reports, eye plaque brachytherapy has a similar survival rate 
compared to surgical enucleation for medium size uveal tumors.(1-3) The Collaborative Ocular 
Melanoma Study (COMS) eye plaque has been popular for decades for its standardization on 
plaque dimensions and number of seeds. Many studies have been published which investigate 
the pros and cons of the COMS eye plaque, although other types of eye plaques are still avail-
able and used at various centers.(4-8) In the conventional COMS eye plaque brachytherapy, 
heterogeneity was introduced by both the gold plaque itself and the Silastic seed carrier (Dow 
Corning, Midland,MI). Chiu-Tsao et al.(5) first studied the impact of the Silastic carrier and 
the gold plaque using Monte Carlo methods and thermoluminescent dosimeters (TLD). TLD 
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 measurements were also performed by de la Zerda et al.(6) and similar results were confirmed. 
These studies showed that the Silastic carrier and the gold plaque could reduce dose by up to 10% 
at a distance of 10 mm on the plaque axis compared with water. The American Brachytherapy 
Society published its recommendations regarding plaque radiotherapy in 2003.(9) Among other 
literature, in 2005 Astrahan et al.(10) reported that for 125I sources, use of the Silastic carrier 
results in a dose reduction of at least 10% in the vicinity of the tumor apex where the dose is 
usually prescribed, compared to absorbed dose to water, and greater than 10% at the tumor 
base and adjacent retina where the dose is closely watched. In another study, Astrahan et al.(4) 
suggested that the Silastic seed carrier insert has caused a list of concerns, because it not only 
reduces doses at the points of interest, but also creates a set of additional difficulties, such as 
handling Silastic insert by forceps behind an L block, and disassembling and sterilization of 
the eye plaque set. According to Astrahan, a water equivalent seed carrier, or just water, is dosi-
metrically desirable; but a thin, gold alloy, seed guide insert would make the job of handling 
and sterilizing eye plaque assembly easier if the insert must be used. Recently,  Melhus and 
Rivard(11) studied COMS eye plaques dose reduction due to the gold alloy and Silastic insert 
using Monte Carlo technique, and published the correction functions for using 6711 125I, model 
200 103Pd and Cs-1 131Cs sources separately. Thomson et al.(12) investigated COMS eye plaque 
with Monte Carlo simulation on its gold plaque intersource effect, as well as the air interface 
and bone effect. Very recently, Zhang et al.(13) studied a COMS eye plaque for its tumor and 
eyeball dose volume histograms when using either 125I or 131Cs sources. Zhang and colleagues 
also verified the accuracy of TG43U1 algorithm and intersource effect through a set of Monte 
Carlo simulations. In another recently published study, Rivard et al.(14) compared the dose cal-
culation methods used in COMS eye plaque calculations. All of the above studies have added 
new understanding and knowledge of the COMS eye plaque. 
The OSU-NAG eye plaque was developed in our clinic and has been used since the early 
1980s to treat uveal melanomas. Figure 1 shows the various designs for the OSU-NAG eye 
plaques.(8) The OSU-NAG eye plaque does not use a Silastic seed carrier, but directly glues 
sources onto its concave surface at conveniently determined and equally spaced locations. For 
tumors with a diameter of 6 mm or less, four sources were used; 6 or 8 sources were used for 
Fig. 1. Several typical designs of the OSU-NAG eye plaques. The upper panel is the OSU-NAG eye plaques used in 
treatments; the lower panel is the corresponding dummy plaque used for determining the suturing location during the 
procedure.
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tumors less than 10 mm but greater than 6 mm, depending on ellipsoidal or circular shapes. 
More sources could be used for larger tumors and plaques. Each time the eye plaque was as-
sembled, these locations were measured by ruler and marked by pen before the sources were 
glued. A 1 mm offset was used to accommodate the curved surface of the plaque when two 
or more circles of sources were used. Compared with COMS eye plaques, the OSU-NAG 
eye plaques have shown some advantages. From the clinical perspective, intraoperatively, the 
larger eyelets in the OSU-NAG design are easier to suture to the sclera than the smaller eyelets 
in the COMS plaque. The OSU-NAG plaque also can be designed and manufactured to treat 
tumors of nearly any shape. For oval shaped tumors, we use oval shaped plaques. For round 
shaped tumors, the round plaques are used. Notched plaques are used for very anterior tumors 
or peripapillary tumors to minimize dose to the optical nerve.(15) Posterior uveal melanomas 
are treated with a plaque which has “rabbit ears”. This rabbit ear plaque is easier to secure to 
the globe than the COMS plaque for the posteriorly located tumors. 
From a radiation physics perspective, the OSU-NAG eye plaque is also advantageous over 
the COMS plaque. In the OSU-NAG eye plaque, the brachytherapy sources are directly glued 
to the plaques onto the predetermined positions, allowing a more accurate dose calculation than 
the COMS, which uses the Silastic carrier on a concave plaque.(5,16) Most planning systems 
have not developed a means for accommodating the dose reduction at locations of interest. 
Because the Silastic seed carrier is made of soft rubber material, when the sources are put in 
the grooves, their locations cannot always be exactly fixed each time, though on most occa-
sions the variation is not significant. It should be noted that the OSU-NAG eye plaque also has 
source positioning errors because the source locations were determined and measured by users 
in every case; however, since it uses fewer sources at simple coordinates, the real  positions of 
sources could be easily measured again. Another issue is the sterilization of eye plaque sets. 
Our initial experience with using COMS eye plaques indicated that Silastic seed carrier makes 
sterilization difficult, as also reported by Astrahan et al.(10) A potential disadvantage to reducing 
the number of sources compared to those used in a standard COMS eye plaque is an increase 
in dose heterogeneity. It should be noted that the modern trend in radiation therapy (e.g., 
IMRT and radiosurgery) is to use more sources of radiation in which each irradiates a sharply 
collimated portion of the tumor in order to achieve homogeneous and highly conformal dose 
distributions with a steep gradient outside the target volume. However, if using fewer sources 
does not impair the dose conformality, this would be clinically advantageous.
This study evaluated the dosimetric quality of the OSU-NAG plaque in treating a sample 
eye tumor using both the 125I and 131Cs sources compared with the 16 mm COMS eye plaque. 
We use 131Cs source in this study simply because this source is becoming more popular for 
brachytherapy applications, although its clinical use for eye plaques has not been reported. 
 
II. MAtErIALS ANd MEtHOdS
A.  COMS eye plaque
The COMS eye plaque is currently available in seven standard sizes with diameters ranging 
from 10 mm to 22 mm in 2 mm increments. Its body is a portion of spherical shell 0.5 mm thick 
with a cylindrical collimating rim.(12) The gold alloy used in the COMS plaque is 77% gold, 
14% silver, 8% copper, and 1% palladium by weight. The brachytherapy sources are loaded in 
molded troughs in the Silastic source carrier insert that fits snugly in the concave aspect of the 
plaque. A 16 mm COMS plaque is used in this study. Thirteen sources of equal source strength 
were placed to treat ocular tumors ranging from 10 to 12 mm in diameter, in compliance with 
the COMS’s recommendation that a tumor-free margin of 2 to 3 mm should be maintained. 
The coordinates of 13 sources in a 16 mm COMS eye plaque, as described by Thompson et 
al.,(12) were used in the calculations. A water-source carrier was chosen in our study to achieve 
a better dose distribution for the implant, as suggested by Astrahan,(4) and also to have a fair 
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comparison with the OSU-NAG eye plaque, which does not have a Silastic source carrier. A 
detailed description of the COMS eye plaques can be found in the literature.(12,14,15) 
B.  OSU-NAG eye plaque
The OSU-NAG plaque is a portion of spherical shell 0.5 mm thick with ellipsoidal or cylin-
drical collimating rim, which would allow users to conveniently select a pertinent shape for a 
particular tumor. The gold alloy used in the OSU-NAG plaque is the same as that used in the 
COMS eye plaques. Figure 2 shows the 16 mm cylindrical OSU-NAG plaque and positions of 
sources used in this study. Unlike the 16 mm COMS eye plaque loaded with thirteen sources 
approximating three isocentric circles, the OSU-NAG eye plaque of this study used only eight 
sources forming two concentric squares at the easily determined locations. The seeds’ locations 
were measured and marked on the surface of plaque before the sources were glued in place. 
After the plaque is assembled, a second physicist checks the coordinates of the seeds using a 
caliber ruler, and if a difference greater than 1 mm is found, enters the real distances into the 
treatment planning system (BrachyVision, Varian Medical, Alto Palo, CA). 
C.  IsoAid IAI-125A 125I source
The IsoAid model IAI-125A Iodine-125 source, manufactured by IsoAid (IsoAid LLC, Port 
Richey, FL) is 4.5 mm in length, with a 0.8 mm outer diameter. The 125I radionuclide is uni-
formly coated on the surface of a 3 mm long and 0.5 mm diameter silver rod, which also serves 
as an X-ray marker. The entire assembly is encapsulated in a 0.05 mm thick titanium tube. The 
dosimetric characteristics of a single source were determined using experimental and theoreti-
cal methods,(17) and its application in COMS eye plaque has also been theoretically studied 
by our group.(13) 
d.  Isoray Cs-1 131Cs source
The IsoRay Cesium-131 brachytherapy source (Model Cs-1 Rev2; IsoRay Medical Inc., 
 Richland, WA) has a physical length of 4.5 mm with 0.1 mm thick caps on each end and an 
outer dimension of 0.8 mm. The source was manufactured by encapsulating an inner core 
with a 0.05 mm thick titanium wall. The center X-ray marker is a 0.25 mm diameter gold 
wire. The wire is coated by a glass and ceramic material. The outside diameter of the source 
inner core is 0.65 mm. The active length of the source is 4.0 mm. The dosimetric behavior of 
a single source has been recently investigated by several groups including ours.(18-20) One of 
our  studies also investigated the dosimetric property of multiple Cs-1 sources in COMS eye 
plaque brachytherapy,(13) as did other groups.(11)
Fig. 2. Schematic diagram of the OSU-NAG eye plaque used in this study. 
170  Zhang et al.: Comparison of OSU-Nag and COMS eye plaque 170
Journal of Applied Clinical Medical Physics, Vol. 13, No. 3, 2012
E.  tumor and eyeball 
This study used a 16 mm COMS and a 16 mm OSU-NAG eye plaque separately to treat a tumor 
which is a part of ellipsoidal volume with a diameter in the major and minor axis of 12 mm and 
a height of 6 mm. (Fig. 3). The origin of the coordinates system is located at the inner sclera 
edge (Z = 0). Tumors of this shape and size are commonly seen at the Ohio State University 
ophthalmology cancer clinic. The diameter of the eyeball was assumed to be 24.6 mm. 
F.  Monte Carlo (MC) simulations  
A Monte Carlo N-particle Transport Code (MCNPX, Version 2.5)(21) was used to calculate the 
doses in water around a 16 mm COMS eye plaque loaded with either 125I or 131Cs sources. 
The sources of IAI-125A 125I and Cs-1 131Cs were benchmarked by Monte Carlo simulations 
in our previous studies(13,17,20) with MCNP5 and MCNP4C. We further verified that the results 
of MCNPX agree with our previous data from MCNP5 and MCNP4c within 1%. There are 
several tally types available in this code for dose calculation. The *F4 calculates the average 
photon energy fluence over a tally cell in MeV/cm2/photon, which is then converted to the dose 
by incorporating the updated mass energy absorption coefficients (cm2/g).(22) We used this tally 
type in all of our dose simulations.  
The photon interaction cross-section file used in this study was the DLC-200 library distrib-
uted by the Radiation Shielding Information Computing Center (RSICC).(23) 
In order to relate the calculated dose rate to the source strength, the Monte Carlo calculated 
dose rate value was converted to dose rate per air kerma (U) using Eqs. (1) and (2): 
  (1)
 
)()()/((
dis
f
g
MeV
DdisgMeVD
  
where, D’ is kerma per photon γ, with the unit of MeV/(g.γ), and f is the ratio of photon/dis-
integration, which is 1.476 for 125I  and 0.729 for 131Cs source.(24) The conversion factor for 
Fig. 3. Schematic diagram of the eye plaque, an eye ball, a sample eye melanoma tumor, and the coordinate system used 
in the Monte Carlo simulations for this study.
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MeV/(g.dis) to Gy/(h.U) was derived as follows and was directly incorporated into the MCNPX 
code in order to obtain the dose rate in the desired units:
  (2)
 
)/(*34.211 UhGyc
disg
MeV
where, c is a conversion factor between the air kerma strength U and contained activity mCi, 
namely 1 U = c mCi (contained). c is determined from the air kerma strength Monte Carlo 
simulation of a single source. 
It should be noted that the air kerma strength of a single source in void space with dry air 
tally cells was first simulated for each source model before the simulation of the eye plaque 
implant in water, and the activity c (in mCi) to ensure that 1 U source strength was determined. 
This activity c was then incorporated into the simulations of the eye plaque implant in water. 
In this way, we eliminated the uncertainties in determining the ratio of apparent/content activ-
ity, which is hard to determine accurately, and made certain that the calculated dose was in the 
unit of Gy/U. Two separate simulations in void space confirmed that c was 1.375 for IAI-125A 
and 2.546 for Cs-1.
In all eye plaque implant calculations, the eye plaque was virtually placed at the center of 
spherical water phantom 15 cm in radius. This phantom size is also used in determining TG43U1 
parameters of a single source of each model. The real size of the eye and surrounding tissue 
is smaller than the phantom used in this study. The purpose of using such a big phantom is 
merely to make our TG43U1 parameters comparable with published data. Therefore, the data 
generated from this study can be used to compare with the results obtained from the clinical 
treatment planning systems.
In order to calculate the DVHs, the spherical tally cells measuring 1 mm in diameter were 
placed uniformly across the tumor and eyeball volumes at 1 mm intervals to score the doses. 
These spherical tally cells were designed not to overlap each other to ensure the events would 
not be counted twice. The coordinates of the tally cells were determined and output to the 
MCNPX input files by a FORTRAN code designed by an author (HZ). The scored doses were 
then analyzed using Origin graphical software (OriginLab Corporation, Northampton, MA) to 
output DVH values. The energy spectrum of 125I was taken from the TG43U1 report.(25) The 
spectrum of the 131Cs source was taken from the NNDC report.(24) 
In all simulations, a cutoff energy of 5 keV was used for both the photon and electron energy 
in order to replicate the NIST’s source calibration condition using the Wide Angle Free Air 
Chamber (WAFAC) detector and also to comply with the TG43U1 recommendation.
A history number of 2 × 108 was used in each simulation. This resulted in the statistical un-
certainty for air kerma strength less than 0.1%, and for the eye plaque implant dose less than 1% 
at the distance on the central axis from the inner sclera edge within 20 mm. When the distance 
is within 30 mm, the overall statistical uncertainty for the implant dose is below 1.5%.
 
III. rESULtS 
A.  Single source data
Prior to the simulations of multiple source implants, the data of a single source of either 
IAI-125A or Cs-1 were generated. The results were in good agreement with the published 
data.(17,19)  Tables 1 and 2 give the radial dose functions of IAI-125A and Cs-1 in a water 
phantom, compared with the published data. The dose rate constant for I-125 source was 
0.979 ± 3% cGy/hr/U (compared to 0.982 cGy/hr/U by Meigooni et al.,(17)), Cs-131 was 1.059 ± 
3% cGy/hr/U (compared to 1.059 cGy/hr/U  by Wang and Zhang(20)). The anisotropy functions 
were also found to be in good agreement with published data (Fig. 4).(20,26)
172  Zhang et al.: Comparison of OSU-Nag and COMS eye plaque 172
Journal of Applied Clinical Medical Physics, Vol. 13, No. 3, 2012
Table 1. IAI-125A radial dose functions obtained by this work compared with a previous study by Meigoonie et 
al.(17) in a water phantom.
  g(r ) g(r ) Ratio
  A. Meigooni et al.(17)  B. This work, 30 cm in diameter spherical water 
 r (cm) (PTRAN) phantom, torus tally cells.  (MCNPX) (A/B)
 0.10  0.710 
 0.20  0.961 
 0.25  0.997 
 0.30  1.015 
 0.35  1.024 
 0.40  1.032 
 0.45  1.038 
 0.50 1.048 1.038 1.010
 0.55  1.034  
 0.60 1.041 1.032 1.009
 0.65  1.032  
 0.70 1.042 1.026 1.016
 0.75  1.024  
 0.80 1.027 1.018 1.009
 0.85  1.016  
 0.90 1.013 1.008 1.005
 0.95  0.999  
 1.00 1.000 1.000 1.000
 1.20  0.976  
 1.30  0.957  
 1.50 0.923 0.931 0.991
 2.00 0.834 0.851 0.980
 2.50 0.750 0.769 0.975
 3.00 0.669 0.688 0.972
 3.50 0.592 0.612 0.967
 4.00 0.523 0.541 0.967
 4.50  0.475  
 5.00 0.399 0.417 0.957
 5.50  0.367  
 6.00 0.305 0.318 0.959
 7.00 0.222 0.242 0.917
 8.00 0.163 0.183 0.891
 9.00 0.126 0.136 0.926
 10.00 0.090 0.102 0.882
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Table 2. Cs-1 radial dose functions obtained by this work compared with a previous study by Wang and Zhang(20) 
in a water phantom.
  gL(r ) gL(r ) Ratio
  A. Wang et al.(20) B. This work, 30 cm in diameter spherical water 
 Z (cm) (MCNP5) phantom, torus tally cells.  (MCNPX) A/B
 0.10  0.961 
 0.20 0.981 0.967 1.014
 0.25 0.988 0.975 1.013
 0.30 0.998 0.979 1.019
 0.35  0.987  
 0.40 1.003 0.988 1.015
 0.45  0.997  
 0.50 1.007 0.997 1.010
 0.55  0.999  
 0.60 1.006 1.001 1.005
 0.65  1.003  
 0.70 1.008 1.001 1.007
 0.75  1.005  
 0.80 1.007 1.001 1.006
 0.85  1.000  
 0.90 1.004 1.002 1.002
 0.95  1.002  
 1.00 1.000 1.000 1.000
 1.20  0.991  
 1.30  0.989  
 1.50 0.963 0.978 0.985
 2.00 0.909 0.934 0.973
 2.50 0.846 0.880 0.961
 3.00 0.778 0.818 0.951
 3.50  0.755  
 4.00 0.641 0.691 0.928
 4.50  0.630  
 5.00 0.516 0.571 0.904
 5.50  0.515  
 6.00 0.410 0.463 0.886
 7.00 0.321 0.370 0.868
 8.00 0.250 0.293 0.853
 9.00  0.230  
 10.00 0.147 0.179 0.821
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B.  Source strengths in two types of eye plaques
Our results indicate that, to achieve a prescription dose of 85 Gy at 6 mm from the inner sclera 
edge, the OSU-NAG eye plaque will need a source strength of 6.16 U/source (49.28 U in to-
tal) and 6.82 U/source (54.56 U in total) for IAI-125A and Cs-1 sources, respectively, but the 
COMS eye plaque will require 4.02 U/source (52.26 U in total) and 4.43 U/source (57.59 U in 
total) for the same source types for a six-day treatment. When the data by Melhus et al.(11) for 
16 mm COMS eye plaque were normalized to a 6 mm prescription point (originally at 5 mm) 
and corrected to our actual treatment time of six days from the seven days used in the original 
study, we found the air kema strength per source obtained from our 16 mm COMS calculation 
to be 13% different from Melhus’ for 131Cs source (Table 3).
Fig. 4. A comparison of the anisotropy functions between this study and published data. 
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C.  doses along the central axis of eye plaque
The doses along the eye plaque axis are shown in Table 3 which lists the doses and their ratios at 
the central axis from two types of eye plaques loaded with two types of brachytherapy sources 
separately, and the doses derived from the Melhus study.(11) Our results indicate that the doses 
from the two plaque types were comparable on the central axis. The 16 mm OSU-NAG plaque 
will give a slightly larger dose than the COMS at short distances (smaller than 6 mm). At the 
inner sclera edge (Z = 0), the dose from the OSU-NAG plaque would be 10% and 12% larger 
than that for the COMS eye plaque, respectively, for I-125 and Cs-131 sources. At 24 mm (this 
point is in the healthy eyeball and the opposite of retina), the OSU-NAG dose would be 6% and 
3% smaller than that of COMS. Since the shorter distance region is in the tumor and the large 
distance is in the healthy part of eyeball, the dosimetric situation generated by the OSU-NAG 
plaque would be clinically unremarkable. Our results agree with the Melhus study within 4% 
and 0.1%, respectively, for the IAI-125A (6711 source was used in the Melhus study) and Cs-1 
sources, except at Z = 0 and -1.0 mm.
Table 3. Dose comparison between of the OSU-NAG and COMS eye plaques. Results by Melhus(11) were normalized 
to the dose at 6 mm and corrected for the treatment time used in this study (6 days vs. 7 days in the Melhus study).
 IAI-125A I-125 CS-1 Cs-131
    Ratio   COMS-Melhus Ratio
  OSU-NAG COMS (OSU-NAG/ OSU-NAG COMS (Cs-1 Cs-131) (OSU-NAG/ 
 Z (cm) (Gy) (Gy) COMS)  (Gy) (Gy) (Gy) COMS)
 -0.1 437.5 415.3 1.05 398.7 365.0 352.0 1.09
 0.0 356.2 323.0 1.10 331.3 294.6 293.8 1.12
 0.1 278.6 256.3 1.09 261.9 236.7 236.7 1.11
 0.2 215.5 200.9 1.07 205.6 190.8 191.5 1.08
 0.3 167.2 162.3 1.03 162.9 154.5 155.8 1.05
 0.4 131.9 129.0 1.02 129.4 126.0 126.7 1.03
 0.5 104.8 104.5 1.00 104.0 102.6 103.1 1.01
 0.6 85.0 85.0 1.00 85.0 85.0 85.0 1.00
 0.7 68.3 70.8 0.96 69.9 70.9 71.1 0.99
 0.8 56.6 59.4 0.95 58.2 59.6 59.3 0.98
 0.9 47.3 50.3 0.94 48.3 50.0 50.0 0.97
 1.0 39.9 42.4 0.94 41.2 42.8 42.6 0.96
 1.2 28.9 30.6 0.95 30.7 31.8  0.97
 1.4 21.5 22.9 0.94 23.3 24.1  0.97
 1.6 16.8 17.7 0.95 18.0 18.6  0.97
 1.8 13.0 13.5 0.96 14.3 14.7  0.97
 2.0 10.3 10.3 0.99 11.5 12.0  0.96
 2.2 8.2 8.4 0.97 9.5 9.7  0.98
 2.4 6.5 6.9 0.94 7.8 8.0  0.97
 2.6 5.5 5.7 0.96 6.5 6.6  0.99
 2.8 4.4 4.8 0.93 5.2 5.6  0.93
 3.0 3.7 4.0 0.92 4.5 4.9  0.92
 Sk (U/source) 6.16   4.02  6.82 4.43 5.03 
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d.  dose volume histogram (dVH) of tumor
Figure 5 shows the comparisons of tumor DVHs from two types of eye plaques at the same 
prescription dose of 85 Gy for two types of sources. The DVHs of the tumor show a minor dif-
ference between two eye plaque types; the use of the OSU-NAG plaque creates slightly hotter 
dose regions than the COMS (longer tail of DVH curve). V120% is the same for both types of 
eye plaques, V150% of the COMS is 5% higher than that seen from the OSU-NAG. 
 
IV. dISCUSSION
In this study, OSU-NAG eye plaque brachytherapy has been compared with the COMS eye 
plaque using 125I and 131Cs brachytherapy sources. In order to have a fair comparison, the Si-
lastic source carrier of the COMS eye plaque was replaced by a water source carrier which does 
not attenuate the dose and, thus, does not need to be modeled in treatment planning systems. 
In this study, we have also avoided the uncertainty of compositions and geometry in Silastic 
source carrier. The results of this study indicated that the 16 mm OSU-NAG eye plaque has 
similar dosimetric characteristics compared with the 16 mm COMS eye plaque using either 
the 125I or 131Cs sources.
A comparison between the current study and the Melhus study demonstrates that the Silastic 
carrier does have a dosimetric impact. However,  the final doses after attenuation correction are 
close to those used in our study, which does not use the Silastic carrier except at the points very 
close to the plaque ( z = -1 mm, 0). The Silastic carrier would significantly increase (13% ~ 
15% in this case) the required source strength necessary to deliver the prescription dose.
Fig. 5. Tumor dose-volume histogram comparison between the 16 mm SU-NAG and 16 mm COMS eye plaques loaded 
with I-125 and Cs-131 sources separately.
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Applying the general concepts, one would expect to see hotter dose regions when fewer 
sources are used. This is confirmed in our study in which the OSU-NAG eye plaque was found 
to have hotter dose regions than COMS eye plaque (Fig. 5). Surprisingly, the OSU-NAG eye 
plaque was found to create only slightly hotter dose regions than COMS eye plaque. In the 
COMS eye plaque, the maximum dose, D 0.1 cc for example, is less than that in OSU-NAG 
eye plaque. D 0.1 cc is 274 Gy for 125I, and 256 Gy for 131Cs, while the values in the OSU-
NAG eye plaque are 281 Gy and 264 Gy, respectively. This implies that a moderate number 
of sources might be enough to maintain adequate dose coverage while avoiding a significant 
increase of hot dose regions. It should be noted that this also could be achieved by using fewer 
seeds in the COMS eye plaques.
In addition, the tumor DVH indicates that the COMS plaque has a 3% larger high-dose 
volume than the OSU-NAG eye plaque at some high-dose regions (greater than 85 Gy). Using 
125I sources, V125, V150, and V200 in COMS eye plaque are 89.6%, 76.5%, and 46.4%; the 
corresponding values in OSU-NAG eye plaque are 89.6%, 71.9%, and 44.5%, respectively. 
This is because brachytherapy sources generally create hot dose zones at the vicinity of the 
sources; thus, using more sources would create more high-dose volumes. Our clinical obser-
vations in over 119 cases,(27) where OSU-NAG eye plaques were utilized, demonstrated that 
the clinical outcomes and complications were comparable to those reported for the COMS 
eye plaques.(28)
Currently, most clinical data involving eye plaque brachytherapy use 125I and 103Pd sources, 
and other sources are not widely used. The radiobiology implication introduced by different 
sources has not been systematically investigated by experimental or clinical trials. 131Cs has 
a much shorter half-life than 125I and 103Pd. Therefore, it would deliver an effective dose in a 
shorter period of time, and require hotter sources than 125I and 103Pd. In addition, the disadvan-
tage of a shorter half-life is that the operating room time has to be more tightly scheduled to 
deliver the radiotherapy (e.g., significantly less/more dose would be delivered if the plaque is 
removed early or late due to an unforeseen emergency situation). So far, the clinical use of 131Cs 
sources in eye plaque brachytherapy has not been reported. Since the initial dose rate of 131Cs 
source is ~ 40% larger than 125I sources, the biology effect of 131Cs eye plaque brachytherapy 
may be quite different. A more comprehensive study involving biological effects to reveal the 
pros and cons of all types of sources is expected.
 
V. CONCLUSIONS
Compared with the fully loaded 16 mm COMS eye plaque, the 16 mm OSU-NAG eye plaque 
can achieve similar dosimetric characteristics with fewer sources. Therefore, from a dosimetric 
perspective, the OSU-Nag plaque can achieve similar results and is an alternative to the COMS 
eye plaque (as are the USC and ROPES plaques).
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